NEW YORK, June 30, 2026, 15:06 EDT
- Pfizer Inc NYSE:PFE slipped 0.9% to $24.14 in afternoon trading. The SPDR S&P 500 ETF Trust NYSEARCA:SPY added 0.9%.
- Pfizer’s implied annual dividend yield climbed to around 7.1% after the stock fell, calculated off its $0.43 quarterly payout.
- Pfizer found a GLP-1 access route in China’s newest reimbursement review, but the initial round covered a lot: 818 submissions for 674 drugs.
Pfizer Inc NYSE:PFE traded lower Tuesday afternoon, trailing the main indexes again and raising fresh questions around the stock’s dividend. The New York Stock Exchange was open for normal trading hours. Its 2026 holiday calendar lists July 3 as the next full-day closure for Independence Day.
The stock changed hands at $24.14 as of 2:50 p.m. EDT, off 23 cents from the previous close. About 32 million shares traded. The SPDR S&P 500 ETF Trust NYSEARCA:SPY added 0.9%. The Health Care Select Sector SPDR Fund (NYSEARCA:XLV) slipped 0.7%. The SPDR S&P Biotech ETF (NYSEARCA:XBI) ticked up 0.3%.
| Intraday move, 2:50 p.m. EDT | Price | Move | What it says |
|---|---|---|---|
| Pfizer Inc NYSE:PFE | $24.14 | -0.9% | Stock trailed the market |
| SPDR S&P 500 ETF Trust NYSEARCA:SPY | $747.33 | +0.9% | Market moved higher |
| Health Care Select Sector SPDR Fund (NYSEARCA:XLV) | $159.56 | -0.7% | Health care slipped, Pfizer fell more |
| SPDR S&P Biotech ETF (NYSEARCA:XBI) | $158.85 | +0.3% | Biotech action didn’t weigh on PFE |
Investors are focused on the yield, not the earnings estimate. Pfizer last week held its quarterly dividend steady at 43 cents a share, with payment set for Sept. 1 to shareholders on record as of July 24. Based on Tuesday’s price, that comes to $1.72 per share annualized, or roughly 7.1%.
This is notable as Pfizer’s payout is now near the size of other big expenses. In Q1, Pfizer paid out $2.4 billion in dividends and $2.5 billion on R&D. The company also said its 2026 outlook does not include share buybacks.
| Pfizer cash and guidance measure | Figure | Investor read-through |
|---|---|---|
| Annualized dividend per share | $1.72 | That’s roughly a 7.1% yield at $24.14 |
| Q1 cash dividends | $2.4 bln | Runs close to the internal R&D bill |
| Q1 internal R&D | $2.5 bln | Pipeline spend remains high |
| 2026 adjusted EPS guide | $2.80-$3.00 | Dividend takes up 57%-61% of the range |
| Buybacks in 2026 guidance | None | Dividend is where the cash goes |
The stock was little changed after Monday’s China headlines. Reuters and the National Healthcare Security Administration said GLP-1 drugs from Pfizer and Innovent Biologics Inc HKG:1801 cleared a first review for potential listing in China’s basic medical insurance drug catalogue.
Mixed read-through here. Pfizer’s ecnoglutide and Innovent’s mazdutide both cleared approval in China for weight loss and type 2 diabetes, but coverage by reimbursement can weigh on prices, even as more patients get access. Innovent shares climbed around 7% on the news, per Reuters.
China’s医保局 said it got 818 submissions from companies for the 2026 review, covering 674 generic drug names. Out of 375 drugs not on the basic list, 334 passed the first check. Public comments are open June 29 to July 5.
For Pfizer, entering China’s GLP-1 market looks more like adding an access channel than solving for earnings in the short term. Reuters said GLP-1 sales via Alibaba and JD.com were about 1.4 billion yuan, or $207 million, for the first quarter, according to Jefferies. That’s a decent market but still small compared to Pfizer’s 2026 revenue target of $59.5 billion to $62.5 billion.
Clinical results last week were mixed. The FDA cleared Pfizer’s IBRANCE for maintenance use in patients with HR-positive, HER2-positive metastatic breast cancer after Phase 3 data showed the regimen cut the risk of progression or death by 24%. Pfizer’s U.S. commercial chief Aamir Malik said IBRANCE is the “first and only CDK4/6 inhibitor” for HR-positive metastatic breast cancer regardless of HER2. Pfizer
Pfizer’s Phase 3 SigVie-002 trial in lung cancer failed to show a statistically significant overall survival benefit with sigvotatug vedotin versus docetaxel in the main analysis. Jeff Legos, head of oncology at Pfizer, said “there is clearly more work to be done.” Solange Peters from Lausanne University Hospital said data in second-line patients still backs more research. Pfizer
Pfizer will report its second-quarter earnings on the morning of Aug. 4. The company has also scheduled a call with analysts that day.
Related articles: NYSE:PFE
